Charles Schwab
HRTX icon

Charles Schwab’s Heron Therapeutics HRTX Stock Holding History

Charles Schwab’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$520K Sell
1,217,463
-158,904
-12% -$127K ﹤0.01% 3227
2026
Q1 		$1.1M Sell
1,376,367
-38,969
-3% -$45.2K ﹤0.01% 2876
2025
Q4 		$1.84M Buy
1,415,336
+138,295
+11% +$171K ﹤0.01% 2776
2025
Q3 		$1.61M Buy
1,277,041
+90,921
+8% +$144K ﹤0.01% 2804
2025
Q2 		$2.46M Buy
1,186,120
+96,671
+9% +$197K ﹤0.01% 2605
2025
Q1 		$2.4M Sell
1,089,449
-16,354
-1% -$31.7K ﹤0.01% 2556
2024
Q4 		$1.69M Buy
1,105,803
+9,418
+0.9% +$15.3K ﹤0.01% 2732
2024
Q3 		$2.18M Sell
1,096,385
-41,411
-4% -$98.9K ﹤0.01% 2684
2024
Q2 		$3.98M Buy
1,137,796
+46,658
+4% +$143K ﹤0.01% 2439
2024
Q1 		$3.02M Buy
1,091,138
+93,937
+9% +$236K ﹤0.01% 2473
2023
Q4 		$1.7M Buy
997,201
+14,192
+1% +$15.6K ﹤0.01% 2667
2023
Q3 		$1.01M Buy
983,009
+239,430
+32% +$341K ﹤0.01% 2794
2023
Q2 		$863K Buy
743,579
+12,453
+2% +$22.2K ﹤0.01% 2820
2023
Q1 		$1.1M Sell
731,126
-66,919
-8% -$168K ﹤0.01% 2703
2022
Q4 		$2M Buy
798,045
+57,039
+8% +$184K ﹤0.01% 2571
2022
Q3 		$3.13M Buy
741,006
+9,951
+1% +$38.9K ﹤0.01% 2449
2022
Q2 		$2.04M Buy
731,055
+15,749
+2% +$63.2K ﹤0.01% 2563
2022
Q1 		$4.09M Buy
715,306
+19,049
+3% +$139K ﹤0.01% 2375
2021
Q4 		$6.36M Sell
696,257
-269
-0% -$2.75K ﹤0.01% 2230
2021
Q3 		$7.45M Buy
696,526
+59,080
+9% +$719K ﹤0.01% 2178
2021
Q2 		$9.89M Buy
637,446
+67,835
+12% +$1.08M ﹤0.01% 2009
2021
Q1 		$9.23M Buy
569,611
+15,870
+3% +$283K ﹤0.01% 2004
2020
Q4 		$11.7M Buy
553,741
+10,657
+2% +$185K ﹤0.01% 1771
2020
Q3 		$8.05M Buy
543,084
+3,248
+0.6% +$50.7K ﹤0.01% 1829
2020
Q2 		$7.94M Buy
539,836
+41,376
+8% +$680K ﹤0.01% 1781
2020
Q1 		$5.85M Buy
498,460
+6,685
+1% +$126K ﹤0.01% 1754
2019
Q4 		$11.6M Buy
491,775
+65,162
+15% +$1.44M 0.01% 1595
2019
Q3 		$7.89M Buy
426,613
+8,875
+2% +$163K ﹤0.01% 1740
2019
Q2 		$7.77M Buy
417,738
+21,519
+5% +$430K ﹤0.01% 1749
2019
Q1 		$9.68M Buy
396,219
+14,714
+4% +$385K 0.01% 1615
2018
Q4 		$9.9M Buy
381,505
+2,460
+0.6% +$67.6K 0.01% 1464
2018
Q3 		$12M Buy
379,045
+50,064
+15% +$1.86M 0.01% 1510
2018
Q2 		$12.8M Buy
328,981
+58,965
+22% +$1.88M 0.01% 1425
2018
Q1 		$7.45M Buy
270,016
+27,082
+11% +$614K 0.01% 1700
2017
Q4 		$4.4M Buy
242,934
+81,735
+51% +$1.33M ﹤0.01% 1985
2017
Q3 		$2.6M Sell
161,199
-9,356
-5% -$147K ﹤0.01% 2192
2017
Q2 		$2.36M Buy
170,555
+1,026
+0.6% +$14.9K ﹤0.01% 2163
2017
Q1 		$2.54M Buy
169,529
+49,211
+41% +$681K ﹤0.01% 2118
2016
Q4 		$1.58M Sell
120,318
-5,950
-5% -$93.4K ﹤0.01% 2272
2016
Q3 		$2.18M Buy
126,268
+14,500
+13% +$269K ﹤0.01% 2089
2016
Q2 		$2.02M Buy
111,768
+8,772
+9% +$171K ﹤0.01% 2068
2016
Q1 		$1.96M Buy
102,996
+2,104
+2% +$41.5K ﹤0.01% 2059
2015
Q4 		$2.69M Buy
100,892
+12,776
+14% +$342K ﹤0.01% 1924
2015
Q3 		$2.15M Buy
88,116
+43,556
+98% +$1.45M ﹤0.01% 2027
2015
Q2 		$1.39M Buy
44,560
+3,610
+9% +$67.9K ﹤0.01% 2264
2015
Q1 		$596K Buy
40,950
+200
+0.5% +$2.25K ﹤0.01% 2569
2014
Q4 		$410K Hold
40,750
– – ﹤0.01% 2708
2014
Q3 		$340K Buy
40,750
+12,250
+43% +$114K ﹤0.01% 2738
2014
Q2 		$352K Buy
+28,500
New +$340K ﹤0.01% 2789

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Charles Schwab's HRTX Position: Q2 2026 in Review

Charles Schwab reduced its Heron Therapeutics (HRTX) stake by 12% in Q2 2026, selling an estimated $127K and leaving 1,217,463 shares worth $520K. The position accounts for ﹤0.01% of the portfolio, ranked #3227.

Charles Schwab first reported a position in HRTX in Q2 2014 and has held it in 49 quarters since. The position peaked at $12.8M in Q2 2018. 162 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Charles Schwab held 1,217,463 shares of Heron Therapeutics worth $520K as of Q2 2026.
  • Charles Schwab sold 158,904 Heron Therapeutics shares in Q2 2026, an estimated $127K.
  • Heron Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3227 holding.
  • Charles Schwab first reported a position in Heron Therapeutics in Q2 2014 and has held it in 49 quarters since.
  • Charles Schwab's Heron Therapeutics position peaked at $12.8M in Q2 2018.
  • 162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.